AIMS: The aim of this study was to evaluate the presence, localisation and extent of myocardial injury as determined by late gadolinium enhancement (LGE) on cardiovascular magnetic resonance (CMR) imaging in patients undergoing transcatheter aortic valve implantation (TAVI). METHODS AND RESULTS: A total of 37 patients, who underwent successful TAVI with a balloon-expandable valve (transapical [TA], n=11; non-TA, n=26), were included. Cardiac biomarker (CK-MB and cTnT) levels were determined at baseline and following TAVI. CMR was performed within a week before and within 30 days following TAVI. Some increase in cardiac biomarkers was detected in 97% of the patients as determined by a rise in cTnT, and in 49% of the patients as determined by a rise in CK-MB. Following TAVI, no new myocardial necrosis defects were observed with the non-TA approach. Nonetheless, all patients who underwent TAVI through the TA approach had new focal myocardial necrosis in the apex, with a median myocardial extent and necrotic mass of 5% [2.0-7.0] and 3.5 g [2.3-4.5], respectively. CONCLUSIONS: Although some increase in cardiac biomarkers of myocardial injury was systematically detected following TAVI, new myocardial necrosis as evaluated by CMR was observed only in patients undergoing the procedure through the TA approach, involving ~5% of the myocardium in the apex.
AIMS: The aim of this study was to evaluate the presence, localisation and extent of myocardial injury as determined by late gadolinium enhancement (LGE) on cardiovascular magnetic resonance (CMR) imaging in patients undergoing transcatheter aortic valve implantation (TAVI). METHODS AND RESULTS: A total of 37 patients, who underwent successful TAVI with a balloon-expandable valve (transapical [TA], n=11; non-TA, n=26), were included. Cardiac biomarker (CK-MB and cTnT) levels were determined at baseline and following TAVI. CMR was performed within a week before and within 30 days following TAVI. Some increase in cardiac biomarkers was detected in 97% of the patients as determined by a rise in cTnT, and in 49% of the patients as determined by a rise in CK-MB. Following TAVI, no new myocardial necrosis defects were observed with the non-TA approach. Nonetheless, all patients who underwent TAVI through the TA approach had new focal myocardial necrosis in the apex, with a median myocardial extent and necrotic mass of 5% [2.0-7.0] and 3.5 g [2.3-4.5], respectively. CONCLUSIONS: Although some increase in cardiac biomarkers of myocardial injury was systematically detected following TAVI, new myocardial necrosis as evaluated by CMR was observed only in patients undergoing the procedure through the TA approach, involving ~5% of the myocardium in the apex.
Authors: Damiano Caruso; Russell D Rosenberg; Carlo N De Cecco; Stefanie Mangold; Julian L Wichmann; Akos Varga-Szemes; Daniel H Steinberg; Andrea Laghi; U Joseph Schoepf Journal: Curr Cardiol Rep Date: 2016-02 Impact factor: 2.931
Authors: Konstantinos C Koskinas; Stefan Stortecky; Anna Franzone; Crochan J O'Sullivan; Fabien Praz; Katazyrna Zuk; Lorenz Räber; Thomas Pilgrim; Aris Moschovitis; Georg M Fiedler; Peter Jüni; Dik Heg; Peter Wenaweser; Stephan Windecker Journal: J Am Heart Assoc Date: 2016-02-19 Impact factor: 5.501
Authors: Mandy Flechsig; Tobias F Ruf; Willi Troeger; Stephan Wiedemann; Silvio Quick; Karim Ibrahim; Christian Pfluecke; Akram Youssef; Krunoslav M Sveric; Robert Winzer; Frank R Heinzel; Axel Linke; Ruth H Strasser; Kun Zhang; Felix M Heidrich Journal: J Clin Med Date: 2020-01-07 Impact factor: 4.241